Boston Scientific (BSX) Gross Margin (2009 - 2026)

Boston Scientific (BSX) has 18 years of Gross Margin data on file, last reported at 69.46% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 62.0% year-over-year to 69.46%; the trailing twelve-month figure through Mar 2026 stood at 69.17% (up 51.0% YoY), and the FY2025 full-year result was 69.01%, up 41.0% from the prior year.
• Gross Margin was little changed at 69.46% in Q1 2026, from 69.6% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 70.63% in Q2 2023 to a low of 67.65% in Q2 2025.
• A 5-year average of 69.01% and a median of 68.85% in 2022 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin jumped 180 bps in 2023 and slumped 152 bps in 2025, its largest moves.
• Tracing BSX's Gross Margin over 5 years: stood at 68.85% in 2022, then grew by 1 bps to 69.23% in 2023, then decreased by 2 bps to 67.86% in 2024, then gained by 3 bps to 69.6% in 2025, then retreated by 0 bps to 69.46% in 2026.
• Business Quant data shows BSX's Gross Margin at 69.46% in Q1 2026, 69.6% in Q4 2025, and 69.93% in Q3 2025.